Progyny is demonstrating structural margin expansion, with gross margin improving to 25.5% in Q2 2026 from 23.7% a year earlier, while operating leverage drives operating margin to 11.4%.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.52+66.1% vs $0.31 | $341M+0.1% vs $341M |
Q3 2026 Aug 6, 2026 | $0.36+7.5% vs $0.33 | $351M+0.4% vs $349M |
Q2 2026 May 7, 2026 | $0.30+17.2% vs $0.26 | $329M+0.6% vs $326M |
Q1 2026 Feb 26, 2026 | $0.15+2.0% vs $0.15 | $318M+3.6% vs $307M |
Shares of Progyny, Inc. (NASDAQ: PGNY - Get Free Report) reached a new 52-week high during mid-day trading on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $35.50 and last traded at $34.0550, with a volume of 175,409 shares changing hands. The stock had previously closed at $30.10.
Progyny NASDAQ: PGNY raised the midpoint of its full-year 2026 guidance after reporting record third-quarter revenue and profitability and securing a record 1.3 million new covered lives during its latest selling season.
Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript
Progyny (PGNY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.45 per share a year ago.
Benchmark PGNY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Progyny, Inc. (PGNY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $34.84 | $2.73B | 31.07 | 10.4% | 6.8% | 19.98% | — | |
| $26.00 | $5.8B | -42.42 | 59% | -5.51% | -30.03% | — | |
| $13.77 | $5.34B | 74.92 | 13.85% | 4.29% | 4.82% | — | |
| $3.51 | $1.22B | 75.16 | 0.57% | 2.07% | 2.61% | — | |
| $83.85 | $106.99B | 9.79 | 7.85% | 2.63% | 14.1% | 3.19% | |
| $293.59 | $77.66B | 12.93 | 11.26% | 2.09% | 14.02% | 2.06% |
Progyny, Inc. (PGNY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Progyny, Inc. (PGNY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 27, 2026·SEC
May 26, 2026·SEC
Get notified when PGNY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Progyny, Inc. (PGNY) stock FAQ — growth, dividends, profitability & financials explained
Progyny, Inc. (PGNY) reported $1.34B in revenue over the trailing twelve months. Revenue was $1.29B in fiscal year 2025. That is 2552% more than the $48.6M of fiscal year 2017.
Progyny, Inc. (PGNY) grew revenue by 5.5% over the trailing twelve months, compared with the twelve months before.
Yes. Progyny, Inc. (PGNY) earned $91.0M in net income over the trailing twelve months (a 6.8% net margin).
Progyny, Inc. (PGNY) had a return on equity (ROE) of 20.0% over the trailing twelve months. That is above the market's typical 10-15%.
Progyny, Inc. (PGNY) generated $219.2M in free cash flow over the trailing twelve months.
